First quarter compared to 2016, Group

» Group net sales increased by 12% to SEK 462,979 (411,834).

» Other operating income amounted to SEK 71,902 (565,286).

» Income after financial items amounted to SEK –19,036,869 (–11,696,747).

» Earnings per share (weighted average) amounted to SEK –0.66 (–0.89).

Significant events during the first quarter  

» Episurf Medical announced and conducted a rights issue and raised approximately SEK 109.5 M prior to transaction costs.

» Episurf Medical is expanded its Clinical Advisory Board.

» Dennis D. Stripe to act as executive chairman.

» Episurf Medical obtained its first granted patents in China.

» Positive patent development in the US for Episurf Medical’s 3D-based damage assessment tool.

» Episurf Medicals CEO Rosemary Cunningham Thomas stepped down – search for new CEO initiated.

Significant events after the first quarter

» Episurf Medical announced that the 50th implantation in Germany of the Episealer® knee implant will take place in the coming days.

» Episurf Medical obtained further granted patent in Australia.

» Episurf Medical strengthened the company’s management group.

» Episurf Medical obtained further granted patent in the US.

» Episurf Medical reached milestone of 200 Implants

For more information, please contact:

Pål Ryfors, acting CEO, Episurf Medical 

Tel: +46 (0) 709 62 36 69


About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website:

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 15 May 2017.